PaxVax continues to evolve its approach for creating an HIV vaccine program, as the knowledge base and immune responses grow.
PaxVax seeks to develop vaccines for diseases that have been overlooked in markets that may not have as much commercial opportunity, but offer a great opportunity to make a social impact and a difference in people’s lives.
PaxVax works with the Walter Reed Army Institute of Research (WRAIR) to carry out the next human clinical trial for its chikungunya vaccine.
PaxVax is developing an important vaccine to fight adenovirus, a major cause of morbidity at military training centers, and Caroline Lyon, MD, MPH, is evaluating the safety and immunogenicity of the new vaccine.
Progress is slow as industry players seek to develop a vaccine for Zika by working alone. PaxVax CEO, Nima Farzan, says global collaboration could help biotech and pharmaceutical companies combat outbreaks like Ebola and Zika before they become pandemics.
The FDA approves the PaxVax oral cholera vaccine for adults aged 18-64 who are traveling to countries affected by cholera.
PaxVax CEO, Nima Farzan, says the company’s prior research and mission to address concerns of pandemic preparedness led to its decision to act quickly in developing a Zika candidate.
PaxVax is among the array of companies working to develop a vaccine for Zika with hopes that it will help advance its social mission to positively impact the spread of infectious diseases in the developing world.
Nima Farzan, PaxVax CEO, says the process for developing vaccines for neglected diseases could be more efficient if economic incentives were provided to biotech companies.
PaxVax launches efforts to develop a vaccine to protect people from being infected by the Zika virus.
PaxVax continues to advance its social mission by researching to develop a Zika vaccine before it spreads to unaffected areas and travelers become affected.
The FDA accepts and grants priority review of the Biologics License Application (BLA) for the PaxVax cholera vaccine.